PDMR Dealings

RNS Number : 3144Z

Oxford Biomedica PLC

20 May 2021

 

PDMR Dealings

Oxford, UK - 20 May 2021:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 19 May 2021, that Dr. James Miskin, Chief Technical Officer of the Group, exercised 19,623 LTIP (2015); 26,210 LTIP (2016); 3,437 DBP (2018) and 5,090 DBP (2019) options at nil cost, and sold all the resulting ordinary shares at 1100.4p per share. Following this transaction Dr. James Miskin continues to hold 131,074 options over ordinary shares.

In addition, Oxford Biomedica was informed on 19 May 2021 that Dr. Jason Slingsby, Chief Business Officer of the Group, exercised 2,411 DBP (2019) options at nil cost, and sold all the resulting ordinary shares at 1100.4p per share. Following this transaction Dr. Jason Slingsby continues to hold 86,158 options over ordinary shares. 

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	James Miskin
2.	Reason for the notification
a)	Position/status	Chief Technical Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Options over ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Exercise of options
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) Nil 54,360
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	54,360 Nil Nil
f)	Date of the transaction	2021-05-18
g)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	James Miskin
2.	Reason for the notification
a)	Position/status	Chief Technical Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Disposal
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £11.004  54,360
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	54,360 £11.003751 £598,163.90
f)	Date of the transaction	2021-05-18
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Jason Slingsby
2.	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Options over ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Exercise of options
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) Nil 2,411
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	2,411 Nil Nil
f)	Date of the transaction	2021-05-18
g)	Place of the transaction	Outside a trading venue

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Jason Slingsby
2.	Reason for the notification
a)	Position/status	Chief Business Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Disposal
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £11.004  2,411
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	2,411 £11.003751 £26,530.04
f)	Date of the transaction	2021-05-18
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a three year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 670 people. Further information is available at www.oxb.com

 

END

 

 

DSHSEAFSSEFSEDI